PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 02:02:30 2024-06-28 pm EDT | ||
| 1.22 EUR | +0.83% |
|
| Current month | -47.41% | ||
| 1 month | -48.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 1.22 | +0.83% |
| 24-06-27 | 1.21 | 0.00% |
| 24-06-26 | 1.21 | +21.00% |
| 24-06-25 | 1 | -29.58% |
| 24-06-24 | 1.42 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 02:02 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1JKL |
| ISIN | DE000VD1JKL4 |
| Date issued | 2024-03-05 |
| Strike | 1,093 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.52 € |
|---|---|
| Lowest since issue | 0.91 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
